Report Store Get Proposal

Home Blog Genetic disorders 2

Genetic Disorders

pharma-news-for-takeda-telix-boehringer

Notizia - Recent Pharma, Healthcare and Biotech Happenings

NeuroNOS’ BA-101 Granted FDA Orphan Drug Status for Glioblastoma; Takeda’s VONVENDI Approval Expanded for Von Willebrand Disease in Adults and Children; Telix Gains FDA Nod on Resubmission Pathway for TLX101-CDx NDA; Saol Therapeutics Receives FDA CRL for SL1009 in Pyruvate Dehydrogenase Complex Deficiency; FDA Grants Breakthrough Therapy Designation to Boehringer’s HERNEXEOS for HER2-Mutant Advanced NSCLC

NeuroNOS Secures FDA Orphan Drug Designation for BA-101 in Glioblastoma NeuroNOS, a biopharmaceutical company specializing in neurological disorders and neuro-oncology and a subsidiary of Beyond Air, announced that the FDA has granted Orphan Drug Designation (ODD) to its lead investigational therapy, BA-101, for the treatment of glioblastoma (GBM). GBM is an aggressive primary brain tumor with limited treatment options, and current standard-of-care therapies, surgery, radiation, and temozolomide, are not curative, with a median survival of under 12 months. “We are pleased to receive orphan drug designation from the FDA for the treatment of glioblastoma,” said A...

Explore More...

pharma-news-for-sobi-gsk-ultragenyx

Sobi’s GAMIFANT Approved by FDA as First Treatment for Macrophage Activation Syndrome in Still’s Disease; GSK Cuts RTS,S Malaria Vaccine Price for Children in Endemic Regions to Under $5; Schrödinger’s SGR-1505 Receives FDA Fast Track Designation for Relapsed/Refractory Waldenström Macroglobulinemia; Ultragenyx’s GTX-102 Granted FDA Breakthrough Therapy Designation for Angelman Syndrome; Eli Lilly’s AMYVID Label Updated by FDA to Support Alzheimer’s Disease Diagnosis

pharma-news-for-celltrion-csl-ocugen

Celltrion Announces FDA Nod for New STEQEYMA Presentation to Broaden Pediatric Use; CSL’s ANDEMBRY Gets FDA Nod as First Factor XIIa Inhibitor for Hereditary Angioedema; Ocugen’s OCU410ST Cleared by FDA to Begin Phase II/III Trial in Stargardt Disease; Milestone Pharmaceuticals Submits FDA Response for CARDAMYST in PSVT; AbbVie’s MAVYRET Approved by FDA as First and Only Therapy for Acute Hepatitis C

thymidine-kinase-2-deficiency-treatment-landscape

Thymidine Kinase 2 Deficiency Treatment: Advances in Therapeutic Strategies and Clinical Development

Types of Mitochondrial Disorders and the Science Behind Them: A Journey from Dysfunction to Discovery

Types of Mitochondrial Diseases and the Science Behind Them: A Journey from Dysfunction to Discovery

pharma-news-for-beam-incannex-kura

Beam’s BEAM-302 Earns FDA Orphan Drug Tag for AATD; Incannex’s IHL-42X Moves to Phase III After FDA Protocol OK; Kura and Kyowa Kirin’s Ziftomenib Gets FDA Priority Review in NPM1-Mutant AML; GSK’s Linerixibat NDA Accepted by FDA for PBC-Linked Pruritus; Ascendis’ TransCon CNP Granted FDA Priority Review for Achondroplasia

niemann-pick-disease-types-therapies-overview

Everything You Need to Know About Niemann-Pick Disease – From Types to Therapies

artificial-intelligence-in-healthcare

Most Promising Artificial Intelligence Applications in the Healthcare Segment

spinal-muscular-atrophy-therapies-in-development

7 Emerging Spinal Muscular Atrophy Therapies Offering Hope for Patients

pharma-news-for-verastem-thermosome-capsida

Eli Lilly’s ZEPBOUND Surpasses WEGOVY in SURMOUNT-5 Trial; Verastem Oncology Secures FDA Approval for AVMAPKI + FAKZYNJA in KRAS-Mutant Ovarian Cancer; Thermosome Gains Orphan Drug Designation for THE001; Beam Therapeutics Receives RMAT Status for BEAM-302 in AATD; Capsida Biotherapeutics Gets IND Clearance for STXBP1 Gene Therapy

spinal-muscular-atrophy-treatment-landscape

Spinal Muscular Dystrophy Treatment: A Deep Dive into Current Therapies and Future Prospects

evolving-congenital-adrenal-hyperplasia-treatment

Congenital Adrenal Hyperplasia Treatment in Transition: Innovations, Setbacks, and Strategic Shifts Shaping the Market

miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment

New Era in Niemann-Pick Disease: A Comparative Review of MIPLYFFA and AQNEURSA

pharma-news-for-regeneron-gilead-neuronos

FDA Approves Sanofi/Regeneron’s DUPIXENT as First New CSU Therapy in Over a Decade; Gilead’s TRODELVY + KEYTRUDA Shows PFS Benefit in PD-L1+ TNBC; Tempest’s TPST-1495 Gets FDA Orphan Tag for FAP; uniQure’s AMT-130 Granted FDA Breakthrough for Huntington’s; NeuroNOS’ BA-102 Secures FDA Orphan Status for Phelan-McDermid Syndrome

pharma-news-for-cellenkos-mirum-soleno

Cellenkos’ CK0801 Granted FDA Orphan Drug Status for Aplastic Anemia; Mirum’s LIVMARLI Gets FDA Nod for Tablet Formulation; SynOx’s Emactuzumab Earns FDA Fast Track for TGCT; Bristol Myers Squibb’s OPDIVO + YERVOY Combo Approved by FDA for First-Line Advanced Liver Cancer; Soleno Launches VYKAT XR, the First FDA-Approved Therapy for PWS-Related Hyperphagia

prader-willi-syndrome-drugs

Prader-Willi Syndrome Drug Market Heats Up: 5 Upcoming Challengers to Soleno’s VYKAT XR

pharma-news-for-amgen-novartis-biogen

Amgen’s UPLIZNA Wins First FDA Nod for IgG4-Related Disease; Aldeyra Gets FDA CRL for Reproxalap in Dry Eye; Novartis’ Vanrafia Snags Accelerated FDA OK for IgAN Proteinuria; Biogen’s BIIB080 Earns Fast Track for Alzheimer’s; Epicrispr’s EPI-321 Cleared by FDA for FSHD

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly